Skip to content.

Aptose closing of US$9.7M Public Offering and Concurrent US$4M Private Placement with Hanmi Pharmaceutical

Date Closed

January 31, 2024

Lead Office

Québec City


13.70 Million USD

On January 31, 2024, Aptose Biosciences Inc. (“Aptose” or the “Company”) announced the closing of the previously announced public offering (the “Public Offering”) of 5,649,122 common shares of the Company (the “Common Shares”) and warrants at a combined offering price of US $1.71 per share. This includes 736,842 Common Shares and warrants pursuant to a full exercise by the underwriter of its over-allotment option. Each Common Share was sold with a warrant to purchase a Common Share (a “Warrant Share”) at an exercise price of US $1.71 per Warrant Share. 

Aptose also announced the closing of the previously announced US $4 million private placement (the “Private Placement”) of Common Shares with Hanmi Pharmaceutical, Inc. (“Hanmi”), yielding ownership of 19.03% of the outstanding Common Shares of the Company. Under the terms of the strategic investment, Hanmi purchased each Common Share at a price of US $1.90, representing an 11% premium over the price of the Common Shares issued as part of the Public Offering. The Company also issued Hanmi warrants to purchase Common Shares at an exercise price of US $1.71 per Warrant Share.

Total gross proceeds from the public offering and private placement were approximately US$13.7 million, excluding underwriting discounts, placement agent commissions and other offering-related expenses. The total number of Common Shares outstanding after the closing of the Public Offering, including the Over-Allotment Option, and Private Placement is 15,706,810 and warrants outstanding are 8,332,163.

Aptose intends to use the net proceeds of the Public Offering and Private Placement to (i) support clinical trials for tuspetinib; (ii) support manufacture of tuspetinib clinical supplies; and (iii) for working capital and general corporate purposes.

Aptose is a clinical-stage biotechnology company developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology.

McCarthy Tétrault assisted Aptose with a team led by Charles-Antoine Souliere that included Farhiyah Shariff, Asma Boudoukha and Annie Poirier-Simard (Business).